|
Sunshine Biopharma, Inc. (SBFM - OTC: BB) |
|
March 4, 2011 Issue |
||
The Most Powerful Name In Corporate News and Information |
||
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | SERVICES | HOME PAGE |
||
Sunshine Biopharma’s Lead Compound is a Topoisomerase II inhibitor – Which is One of the Most Important Targets for Treating Aggressive Cancer |
||
Company Profile:
Sunshine Biopharma, Inc.
is a pharmaceutical company focused on the research, development and
commercialization of drugs for the treatment of various forms of cancer. |
|
|
Interview conducted by: Lynn Fosse, Senior Editor, CEOCFOinterviews.com, Published – March 4, 2011
Dr. Slilaty: Sunshine Biopharma is focused on the research, development and commercialization of drugs for the treatment of various forms of cancer.
Dr. Slilaty: At present our lead compound is a Topoisomerase II inhibitor. Topoisomerase II is one of the most important targets for treating aggressive cancer.
Dr. Slilaty: Topoisomerase II is an enzyme that aggressive cancer cells make too much of. When the cell is able to make a lot of the Topoisomerase II enzyme, it becomes able to proliferate and metastasize; so, if you can inhibit or destroy the activity of Topoisomerase II, you would then be able to prevent cancer cells from spreading.
Dr. Slilaty: There are treatments, there is a drug that is considered to be a Topoisomerase II inhibitor, but it actually doesn’t work as such. Our drug, Adva-27a, is ten times more effective than any drug on the market for treating aggressive cancer.
Dr. Slilaty: We have done a lot of preclinical testing and we are now positioned to begin doing animal studies and immediately after begin stage I clinical trials.
Dr. Slilaty: Initially we are working on the so-called multi-drug resistant breast cancer. In a certain group of breast cancer patients, as well as over time in a lot of cancer patients, the tumor becomes resistant to all treatment and at that point there is not much to do by way of existing therapy. Our drug works extremely well in killing multi-drug resistant breast cancer cells. That is our first indication.
Dr. Slilaty: We developed it ourselves in collaboration with a government research lab in France.
Dr. Slilaty: We have done testing in France and now we are carrying out testing at the Binghamton University in New York.
Dr. Slilaty: We are in good shape. We have sufficient funds to operate and we are planning to apply for support through granting agencies in the U.S. through our collaboration with Binghamton University.
Dr. Slilaty: It is a bit early because we have not publicized what we have yet.
Dr. Slilaty: We imagine that at the end of Phase I, once we publish the results of human trials, we expect that large pharmaceutical companies will want to probably step in and buy it from us at that point.
Dr. Slilaty: Another indication we are looking to study is prostate cancer and as with breast cancer, our drug has proven to be very effective in treating aggressive forms of prostate cancer. That would be a second indication.
Dr. Slilaty: The similarity is that different types of cancer cells make different amounts of this Topoisomerase II enzyme. The more Topoisomerase II the cell makes, the more effective our drug is at killing that cell. What that means is when prostate cancer become metastatic, which is when the cell starts making a lot of Topoisomerase II, is when our drug becomes very effective in treating that cancer. There are other types of cancer, like small cell lung cancer where initially, or right at the point of diagnosis of this type of cancer, the cell is already making a lot of Topoisomerase II and it is very aggressive at the onset. In fact, patients that are diagnosed with small cell lung cancer only have three to six months to live. We have already shown in the lab that our drug works extremely well in terms of killing this type of lung cancer cells.
Dr.
Slilaty:
We believe that we will be able to begin the human trials optimistically
about twelve months from now, but more realistically within the next
eighteen months. Dr. Slilaty: Our technology is unique. We are the only company that has a Topoisomerase II inhibitor. We have two patents covering our lead compound and our technology. So from the intellectual property side we are very well protected and no one can enter the area we are in. We are not developing anything that is a so-called me-too drug; our technology is unique.
Dr. Slilaty: Absolutely! If our drug proves to do in humans exactly what we think, it will be worth over a billion dollars.
Dr. Slilaty:
We are a very serious group of oncologists who are trying to provide therapy
to save lives and bring value to our shareholders. |
||
Topoisomerase II is an enzyme that aggressive cancer cells make too much of. When the cell is able to make a lot of the Topoisomerase II enzyme, it becomes able to proliferate and metastasize; so, if you can inhibit or destroy the activity of Topoisomerase II, you would then be able to prevent cancer cells from spreading. - Dr. Steve N. Slilaty |
||
|
||
|
ceocfointerviews.com does not purchase or
make
recommendation on stocks based on the interviews published.